尔康制药(300267) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥324,541,963.43, representing a 39.32% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥1,941,249.06, a significant increase of 106.11% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥2,211,584.10, up 106.43% from the previous year[5] - Basic earnings per share for the period were ¥0.0009, an increase of 105.84% year-on-year[5] - Total operating revenue for the current period reached ¥1,006,423,651.81, an increase of 17.8% compared to ¥854,289,240.97 in the previous period[22] - Net profit for the current period was ¥27,110,714.45, a significant recovery from a net loss of ¥26,889,704.70 in the previous period[23] - The profit attributable to shareholders of the parent company was ¥39,575,891.64, compared to a loss of ¥25,467,316.32 in the previous period[23] Cash Flow and Assets - The operating cash flow for the year-to-date period was ¥211,684,847.35, reflecting a 179.22% increase[5] - The company's cash and cash equivalents at the end of the reporting period amount to ¥709,202,365.93, an increase from ¥698,537,949.74 at the beginning of the period[19] - The total current assets are ¥1,774,063,309.93, compared to ¥1,717,081,656.36 at the beginning of the period, reflecting a growth of approximately 3.3%[20] - Total assets at the end of the reporting period were ¥5,202,672,968.23, a slight increase of 0.06% from the end of the previous year[5] - The ending balance of cash and cash equivalents was CNY 478,021,035.45, compared to CNY 453,787,274.52 in the previous period[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 49,105[15] - The largest shareholder, Shuai Fangwen, holds 41.38% of shares, totaling 853,574,906 shares, with 640,181,179 shares pledged[15] Expenses and Liabilities - The company reported a significant decrease in sales expenses by 41.33% to ¥4,268.68 due to reduced promotional costs[11] - Financial expenses increased by 286.16% to ¥353.66, primarily due to decreased exchange gains[11] - Total liabilities decreased slightly to ¥790,633,212.03 from ¥797,540,680.70, indicating a reduction of 0.9%[21] - Total operating costs amounted to ¥985,154,942.51, up from ¥893,553,175.63, reflecting a growth of 10.3%[22] Research and Development - Research and development expenses were ¥30,243,874.28, down from ¥34,116,241.19, showing a decrease of 11.1%[23] - The company has completed the writing of 3 new software copyrights and 2 invention patents, with one patent already receiving preliminary approval[17] Investments and Projects - The company is investing $10 million in a comprehensive formulation production project in Tanzania, expected to complete equipment debugging by Q4 2025[16] - A new company, Hengzhenglong Co., Ltd., has been established in Cambodia with a registered capital of $2 million to support business development[17] - The subsidiary, Hangzhou Land Intelligent Technology Co., Ltd., has applied for and obtained operating qualifications for various medical devices, enhancing its market position in AI technology applications[17] Comprehensive Income - Other comprehensive income after tax was reported at -¥17,720,724.55, an improvement from -¥85,012,752.50 in the previous period[23] - Total comprehensive income attributable to the parent company was CNY 21,715,433.97, a decrease of CNY 110,445,017.59 compared to the previous period[24]